Axogen

Youtube Subscribe

Open: 9.41 Close: 9.17 Change: -0.24

Are you still looking for information about Axogen Company Inc Stock? An AI summarized it for you.

This document will help you to evaluate Axogen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Axogen are: revenue, Axogen, AxoGen, expect, fullyear, range, year, and the …

Concept Map

Semantic Network

Stock Summary

AxoGen, Inc. develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft. Ax.

Today's Summary

AxoGen (AXGN) posts revenues of $36.66 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 2.41%. The company is scheduled to announce Q1 earnings results on Tuesday, May 9th.

Today's News

AxoGen expects full-year revenue in the range of $154 million to $159 million. Axogen anticipates that gross margins will return to around 80% by the end of the year. AxoGen expects full-year revenue in the range of $154 million to $159 million. The company is scheduled to announce Q1 earnings results on Tuesday, May 9th. Axogen expects full-year revenue in the range of $154 million to $159 million. AxoGen shares have dropped 3% since the beginning of the year. AxoGen (AXGN) posts revenues of $36.66 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 2.41%. JMP Securities analyst David Turkaly maintained a Buy rating on Axogen today and set a price target of $20.00. Currently, the analyst consensus on Axosgen is a Strong Buy. Axogen expects full-year revenue in the range of $154 million to $159 million. Marc Began is AxoGens new EVP and General Counsel. Axogen shares have dropped 3% since beginning of the year.

Stock Profile

"AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida."

Keywords

The game is changing. There is a new strategy to evaluate Axogen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Axogen are: revenue, Axogen, AxoGen, expect, fullyear, range, year, and the most common words in the summary are: axogen, earnings, news, q1, snapshot, inc, market, . One of the sentences in the summary was: The company is scheduled to announce Q1 earnings results on Tuesday, May 9th.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #axogen #earnings #news #q1 #snapshot #inc #market.

Read more →

Youtube Subscribe

---